Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim that interferon alfa products/BESREMi may cause or aggravate serious disorders covering neuropsychiatric, autoimmune/endocrine, ischemic (cardiovascular and colitis), and infectious complications is directly supported by multiple label warnings and contraindications (Sections 5.1, 5.2, 5.3, 5.4, 5.7, and 4).
Category Scores
Accurate Statements
Risk of serious disorders that interferon alfa products may cause or aggravate—neuropsychiatric, autoimmune, ischemic, and infectious disorders.
Supported by label warnings that interferon alfa products including BESREMi can cause life-threatening/fatal neuropsychiatric reactions (5.1, and contraindication in 4), autoimmune/endocrine toxicity (5.2 and contraindication in 4), cardiovascular/ischemic toxicities including coronary artery ischemia (5.3) and fatal/serious hemorrhagic/ischemic colitis (5.7), and decreased blood counts/leukopenia increasing infection risk with reported infection/serious infection rates (5.4).
Unsupported Statements
Contradictions
Important Omissions
No label-quoted details for the exact phrases 'cause or aggravate' or a symptom list for each disorder category; however, the AI did not provide further granularity beyond the high-level category risk, which is still covered by the cited warning sections.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated output is a high-level safety characterization consistent with label warnings; it does not provide dosing, specific patient selection, or treatment instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement
Optionally cite specific warning subsections per category (e.g., 5.1 neuropsychiatric, 5.2 endocrine/autoimmune, 5.3 ischemic cardiovascular, 5.4 infectious via leukopenia, 5.7 ischemic colitis) if producing a more detailed safety statement.